Janus Henderson Group PLC Buys 602,609 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Janus Henderson Group PLC lifted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 18.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,956,878 shares of the company's stock after purchasing an additional 602,609 shares during the quarter. Janus Henderson Group PLC owned 6.92% of Structure Therapeutics worth $173,623,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Sandia Investment Management LP bought a new position in shares of Structure Therapeutics in the 2nd quarter valued at approximately $39,000. Assetmark Inc. boosted its stake in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after purchasing an additional 719 shares in the last quarter. Quarry LP bought a new stake in shares of Structure Therapeutics during the second quarter worth $79,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after acquiring an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC bought a new stake in Structure Therapeutics in the third quarter valued at about $202,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Price Performance

Shares of GPCR stock traded up $0.30 on Wednesday, reaching $33.55. 1,099,198 shares of the company were exchanged, compared to its average volume of 783,816. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -45.34 and a beta of -3.41. The company has a 50-day moving average of $37.66 and a 200-day moving average of $39.38. Structure Therapeutics Inc. has a one year low of $26.61 and a one year high of $64.45.

Analysts Set New Price Targets

GPCR has been the topic of several recent analyst reports. HC Wainwright initiated coverage on Structure Therapeutics in a report on Wednesday. They set a "buy" rating and a $80.00 price objective on the stock. JMP Securities cut their price objective on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a report on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $85.67.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.